Full Text:
<2577>
CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 3
Clicked: 4997
Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer
| ||||||||||||||
Xinguo Jiang. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer[J]. Journal of Zhejiang University Science B, 2015, 16(1): 44-45.
@article{title="Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer",
author="Xinguo Jiang",
journal="Journal of Zhejiang University Science B",
volume="16",
number="1",
pages="44-45",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1400352"
}
%0 Journal Article
%T Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer
%A Xinguo Jiang
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 1
%P 44-45
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1400352
TY - JOUR
T1 - Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer
A1 - Xinguo Jiang
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 1
SP - 44
EP - 45
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1400352
Abstract: macrophages are among the most abundant immune cells in the tumor microenvironment, where they are known as tumor-associated macrophages (TAMs). Substantial evidence indicates that TAMs generally play protumoral roles in the primary as well as metastatic sites (Noy and Pollard, 2014). TAMs are also known to interfere with several tumor therapeutic modalities, such as chemotherapy, irradiation, and immunotherapy. In general, depletion of M2-like TAMs or reprogramming them into M1-like phenotype enhances the efficacy of these therapies (Rolny et al., 2011; de Palma and Lewis, 2013; Germano et al., 2013).
[1]de Palma, M., Lewis, C.E., 2013. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell, 23(3):277-286.
[2]DeNardo, D.G., Brennan, D.J., Rexhepaj, E., et al., 2011. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov., 1(1):54-67.
[3]Germano, G., Frapolli, R., Belgiovine, C., et al., 2013. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell, 23(2):249-262.
[4]Jiang, X., 2014. Harnessing the immune system for the treatment of breast cancer. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(1):1-15.
[5]Noy, R., Pollard, J.W., 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1):49-61.
[6]Rolny, C., Mazzone, M., Tugues, S., et al., 2011. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 19(1):31-44.
[7]Ruffell, B., Chang-Strachan, D., Chan, V., et al., 2014. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell, 26(5):623-637.
[8]Stewart, C.A., Metheny, H., Iida, N., et al., 2013. Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J. Clin. Invest., 123(11):4859-4874.
[9]Trinchieri, G., 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol., 3(2):133-146.
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>